First-of-its-kind study reveals predictive factors for outcomes of advanced stage AL amyloidosis
Study shines light on factors indicative of treatment outcomes for stage IIIb AL amyloidosis, a critical, rare, and understudied condition
2023-08-15
(Press-News.org) (WASHINGTON, August 15, 2023) – Early improvements in cardiac and hematologic parameters may predict better survival outcomes for patients being treated for stage IIIb AL amyloidosis, a deadly disease with a median survival of 4-6 months caused by abnormal protein buildup, according to new research released today in Blood Advances.
Amyloidosis occurs when normal proteins in the body misfold and form amyloid deposits in vital organs and tissues, which can lead to organ dysfunction, failure, and death. The prognosis for patients with advanced cardiac amyloidosis is extremely poor, but clinicians have little data to turn to to guide treatment regimens. This study reveals how early responses to treatment may predict survival outcomes.
“While AL amyloidosis is a rare condition, symptoms can mimic those of many other more common diseases, like diabetes, hypertension, autoimmune disorders, and connective tissue diseases, making it difficult for clinicians to diagnose it early,” explained Vaishali Sanchorawala, MD, Director of the Amyloidosis Center at Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, and senior author of this study. “By understanding the significance of early treatment responses at one and three months after beginning treatment, we can better guide our approaches to therapy and improve patient outcomes.”
Researchers reviewed data from 142 patients with newly diagnosed stage IIIb AL amyloidosis with advanced cardiac involvement from 2007 until 2022. Patients were included after 2007 when bortezomib-based treatment regimens became available for the treatment of AL amyloidosis, after their success in treating myeloma. After 60 months of follow-up, patients exhibited a median overall survival of nine months. Several baseline factors were predictors of worse survival including the onset of symptoms to diagnosis of greater than six months, bone marrow plasma cell count of more than 10%, higher troponin I levels (a marker of heart damage), and walking a distance of less than 200 meters in six minutes. Treatment with bortezomib and daratumumab-based regimens led to improved survival.
Patients who experienced early hematologic (within one month) and cardiac (within three months) response had significantly longer overall survival outcomes. Patients achieving a very good partial hematologic response at one month following treatment had a prolonged survival of 47 months.
“Stage IIIb AL amyloidosis with advanced cardiac involvement does not have to be a death sentence,” emphasized Dr. Sanchorawala. “We see patients who live four to five years after being diagnosed, and studies like this one helps us understand what factors may indicate a better prognosis. These findings help us to appropriately tailor our treatment regimens to achieve optimal outcomes.”
Dr. Sanchorawala reiterated that to advance treatment and improve overall survival for patients living with this condition, we must prioritize their involvement in clinical research.
“Our ability to advance science and improve patient outcomes depends on rare disease-focused clinical trials,” she said.
ASH is currently in the process of developing evidence-based clinical practice guidelines on the diagnosis of amyloidosis (both types, AL and ATTR) that reflect the latest evidence about the disease to help ensure the medical community can better diagnose and treat amyloidosis and people with amyloidosis can make the best decisions for their care. Learn more about all ASH Clinical Practice Guidelines.
# # #
Blood Advances (www.bloodadvances.org) publishes more peer-reviewed hematology research than any other academic journal worldwide and is an online only, open access journal of the American Society of Hematology (ASH), the world’s largest professional society concerned with the causes and treatment of blood disorders.
Blood Advances® is a registered trademark of the American Society of Hematology.
Contact:
Kira Sampson, American Society of Hematology
ksampson@hematology.org; 202-499-1796
END
ELSE PRESS RELEASES FROM THIS DATE:
2023-08-15
In a study published in the journal Genes & Diseases, researchers from Naval Medical University and Soochow University conducted an in-depth investigation into the genomic landscape of schistosomiasis-associated colorectal cancer (SA-CRC). By utilizing whole exome sequencing on tumor tissues and their non-tumor counterparts obtained from thirty SA-CRC patients diagnosed at Changzheng Hospital from 2014 to 2020, the team successfully identified 2476 nonsynonymous mutations spanning across 1978 genes. This intricate analysis revealed a lower median tumor mutation burden (TMB) in SA-CRC compared to sporadic colorectal cancer (S-CRC), ...
2023-08-15
DALLAS, August 15, 2023 — Fifteen students from coast to coast are joining the American Heart Association, a global force for healthier lives for all, to champion their peers to live heart healthy. Representing a diversity of backgrounds and experiences, these youth selected as national volunteer Youth Heart Ambassadors for the association’s in-school programs, Kids Heart Challenge™ and American Heart Challenge™ will share how heart disease and stroke have impacted their lives while encouraging others to ...
2023-08-15
(LOS ANGELES) – August 15, 2023 - A team of researchers from the Terasaki Institute for Biomedical Innovation (TIBI) and the University of Nebraska Medical Center (UNMC) has been awarded a multimillion-dollar grant from the National Institutes of Health to develop a superior, multi-pronged wound treatment for diabetic foot ulcers (DFUs).
DFUs remain a significant complication resulting from dysregulated internal pathophysiological conditions in diabetic patients. The unresolved diabetic wounds affect patients’ quality of life and can result in amputations ...
2023-08-15
Protein from two ounce-equivalents (oz-eq) of animal-based protein foods provides greater essential amino acids (EAA) bioavailability than an equal two oz-eq of plant-based protein foods, according to scientists at Purdue University.1
The protein quality of a food or meal (i.e., the EAA content of a meal) is a major factor in determining how the body can use amino acids for muscle and whole-body protein building.2-4
The Dietary Guidelines for Americans (DGAs) puts an emphasis on consuming a variety of protein foods based on ounce-equivalent portions with similar nutritional ...
2023-08-15
HOUSTON – (Aug. 15, 2023) – Rice University chemists have discovered that tiny gold “seed” particles, a key ingredient in one of the most common nanoparticle recipes, are one and the same as gold buckyballs, 32-atom spherical molecules that are cousins of the carbon buckyballs discovered at Rice in 1985.
Carbon buckyballs are hollow 60-atom molecules that were co-discovered and named by the late Rice chemist Richard Smalley. He dubbed them “buckminsterfullerenes” because their atomic structure reminded him of architect Buckminster Fuller’s geodesic domes, and the “fullerene” family has grown to include dozens of hollow ...
2023-08-15
HOUSTON – (Aug. 15, 2023) – Bioengineers can tailor the genomes of cells to create “cellular therapies” that fight disease, but they have found it difficult to design specialized activating proteins called transcription factors that can throw the switch on bioengineered genes without occasionally turning on some of the cell’s naturally occurring genes.
In a study published online in Cell, bioengineers from Rice University, Boston University, Harvard Medical School, Dartmouth College and Harvard University’s Wyss Institute showed they could all but eliminate such “off-target” gene ...
2023-08-15
SAN FRANCISCO, Aug. 15, 2023 — “Back-to-school” season means buying pens and paper, figuring out the new bus route, and … earaches. Doctors typically treat these infections with antibiotics, but children don’t always complete the full course, accelerating resistance to these medications. Today, researchers report developing a single-use nanoscale system that’s unlikely to generate resistance. Using a compound similar to bleach in test animals, they show it can kill off one type of bacterium that causes ear infections, and it could someday be easily applied as a gel.
The researchers will present their results today at the fall meeting of the American Chemical ...
2023-08-15
SAN FRANCISCO, Aug. 15, 2023 — Aloe barbadensis, commonly known as aloe vera, has been used for thousands of years to treat skin ailments, promote digestive health and heal wounds. But while aloe vera gel is in high demand, the peels are thrown away as agricultural waste. Today, scientists report that these peels, or rinds, can ward off bugs, acting as a natural insecticide. They have identified several bioactive compounds in extracts from the peels that deter insects from feasting on crops.
The researchers will present their results at the fall meeting of the American Chemical Society (ACS). ACS Fall ...
2023-08-15
SAN FRANCISCO, Aug. 15, 2023 — Young vegetables known as microgreens are reputed to be particularly good for health. Now, researchers are trying to find out if microgreens — which can easily be grown at home — are the superfood they’re claimed to be, and how they compare to mature veggies. Results to date show their nutritional profiles differ, as do their effects on gut bacteria. Yet, tests in mice suggest that both microgreen and mature vegetables can limit weight gain.
The researchers will present their results today at the fall meeting ...
2023-08-15
SAN FRANCISCO, Aug. 15, 2023 — To explore why prostate cancer disproportionately sickens and kills Black men, researchers are looking to another disorder, diabetes, which alters metabolism. They used this approach in a preliminary clinical trial and today report the identification of four metabolism-related biomarkers linked to an increased risk of metastatic prostate cancer in men of West African heritage. This discovery could lead to improved testing and treatments for these patients.
The researchers will present their results at the fall ...
LAST 30 PRESS RELEASES:
[Press-News.org] First-of-its-kind study reveals predictive factors for outcomes of advanced stage AL amyloidosis
Study shines light on factors indicative of treatment outcomes for stage IIIb AL amyloidosis, a critical, rare, and understudied condition
